Skip to main content
skill CX Codex

earnings-product-pipeline — Claude Code skill: product pipeline

earnings-product-pipeline extracts product development data from earnings calls: clinical trial status, regulatory submissions, launch timelines.

MIT 265 installs ★ 132 updated 2026-06-05

Install into Claude Code · Skills CLI (Vercel) All methods and platforms ↓
npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code
Open on GitHub

What earnings-product-pipeline does

The skill parses earnings call transcripts and collects product pipeline information. Looks for trial phases (Phase 1, Phase 2, Phase 3), regulatory filings (IND, NDA, BLA), launch dates, and R&D investments. Returns a structured table with key milestones, timelines, trial status, and transcript page references.

Requires Octagon MCP configured — queries fail without it. Supports filtering by data type: you can request only regulatory updates or only launch timelines. Generates follow-up questions for deeper analysis and builds a catalyst calendar with risk assessment for each event.

Query examples: Extract product development and pipeline updates from MRNA's latest earnings call discussion, What regulatory submissions or approvals were discussed in PFE's call?, Extract clinical trial updates from JNJ's earnings transcript.

What it helps with

  • extract clinical trial data from earnings calls
  • collect a company's regulatory submission timeline
  • track product pipeline progress through transcripts
  • build a catalyst calendar with Phase 3 data dates
  • find R&D priorities in earnings reports

Example prompts for the agent

  • Extract product pipeline updates from MRNA's latest earnings call
  • What regulatory submissions were discussed in PFE's earnings call?
  • Collect clinical trial information from JNJ's earnings transcript

How to install earnings-product-pipeline

1Skills CLI (Vercel)

npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code

2Manually: put the files in place

~/.claude/skills/earnings-product-pipeline/SKILL.md

Copy the whole skill folder; for one project use .claude/skills/earnings-product-pipeline/

Step by step, with commands for each platform: How to install skills in Claude Code: five ways

Questions about earnings-product-pipeline

How to install earnings-product-pipeline in Claude Code?

Run npx skills add OctagonAI/skills --skill earnings-product-pipeline -a claude-code, then open ~/.claude/skills/earnings-product-pipeline/SKILL.md.

What does earnings-product-pipeline do?

Pulls product development data from earnings calls: trial status, regulatory submissions, launch timelines. Returns a structured table with dates and transcript page references.

What does earnings-product-pipeline require?

Octagon MCP configured. Without it, the skill cannot query earnings calls.

Source text

SKILL.md · MIT
---
name: earnings-product-pipeline
description: Extract product development and pipeline updates from earnings calls, including clinical trial progress, regulatory submissions, and launch timelines.
---

# Earnings Product Pipeline

Extract product development and pipeline updates from earnings call transcripts, including R&D milestones, clinical trial progress, regulatory submissions, and product launch timelines.

## Prerequisites

Ensure Octagon MCP is configured. See [references/mcp-setup.md](references/mcp-setup.md) for installation instructions.

## Workflow

### Step 1: Extract Pipeline Updates

Use the Octagon MCP to analyze product pipeline discussions:

```
Extract product development and pipeline updates from <TICKER>'s latest earnings call discussion.
```

### Step 2: Targeted Pipeline Analysis

Focus on specific aspects of product development:

```
# Full Pipeline
What product pipeline updates were discussed in <TICKER>'s earnings call?

# Clinical Trials
Extract clinical trial updates from <TICKER>'s earnings transcript.

# Regulatory Progress
What regulatory submissions or approvals were discussed in <TICKER>'s call?

# Launch Timeline
Extract product launch timelines from <TICKER>'s earnings call.

# R&D Investments
What R&D priorities were highlighted in <TICKER>'s earnings transcript?

# Stage Progression
Which products advanced to new stages in <TICKER>'s pipeline?
```

## Expected Output

The skill returns structured pipeline analysis including:

| Component | Description |
|-----------|-------------|
| Development Milestones | Key progress updates |
| Clinical Trials | Trial status and data timelines |
| Regulatory Submissions | FDA/EMA filings and approvals |
| Launch Timeline | Expected commercialization dates |
| Portfolio Overview | Stage-by-stage breakdown |
| Follow-up Questions | AI-generated questions for deeper research |
| Source Citations | Transcript page references |

## Example Query

```
Extract product development and pipeline updates from MRNA's latest earnings call discussion.
```

## Example Response

**Moderna, Inc. (MRNA) Product Development and Pipeline Updates (Q4 2024)**

Moderna highlighted key product development and pipeline updates in their earnings call:

**Product Development Milestones**
- **Methylmalonic Acidemia (MMA) Test Products**: Achieving critical milestones with three regulatory submissions filed
- **CMV Vaccine**: Anticipating final Phase 3 results in 2025
- **Flu and Norovirus Vaccines**: Both in Phase 3 trials, with data timelines contingent on case accrual
- **INT Adjuvant Melanoma**: Progress dependent on patient accrual
- **PA (Pneumonia) Vaccine**: Awaiting data from a registrational study, with plans to initiate a new MMA registrational study within the year

**Portfolio Overview**
- Approved Products: 2
- Advanced-Stage Candidates: 3
- Phase 3/Pivotal Studies: 6 ongoing

The updates underscore Moderna's expanding mRNA platform pipeline.

**Follow-up Questions**
- What are the specific regulatory submissions for MMA test products?
- What are the enrollment targets for the flu and norovirus Phase 3 trials?
- What are the primary endpoints for the INT adjuvant melanoma study?

**Source**: MRNA_Q42024, Page: 4

## Pipeline Stage Framework

### Development Stages

| Stage | Description | Probability of Success |
|-------|-------------|------------------------|
| Discovery | Early research | 5-10% |
| Preclinical | Lab/animal studies | 10-15% |
| Phase 1 | Safety, dosing | 15-25% |
| Phase 2 | Efficacy signal | 25-40% |
| Phase 3 | Pivotal trials | 50-70% |
| Regulatory | Under review | 85-95% |
| Approved | Marketed | 100% |

### Pipeline Progression Signals

| Signal | Interpretation |
|--------|----------------|
| "Initiated Phase X" | Moving forward |
| "Positive interim data" | Encouraging results |
| "Met primary endpoint" | Success, advancing |
| "Did not meet endpoint" | Failure, reassess |
| "Regulatory submission" | Final stages |
| "FDA priority review" | Accelerated timeline |

## Clinical Trial Analysis

### Trial Status Categories

| Status | Description | Next Milestone |
|--------|-------------|----------------|
| Enrolling | Recruiting patients | Full enrollment |
| Fully Enrolled | Recruitment complete | Data readout |
| Ongoing | Treatment/observation | Primary endpoint |
| Data Collection | Gathering results | Analysis |
| Readout Expected | Results imminent | Announcement |

### Trial Data Timeline

| Trial Phase | Typical Duration | Data Timing |
|-------------|------------------|-------------|
| Phase 1 | 1-2 years | End of phase |
| Phase 2 | 2-3 years | Interim + final |
| Phase 3 | 2-4 years | Interim + final |
| Regulatory | 6-12 months | Approval decision |

## Regulatory Progress Tracking

### Submission Types

| Type | Description | Timeline |
|------|-------------|----------|
| IND | Investigational New Drug | Pre-Phase 1 |
| NDA | New Drug Application | Post-Phase 3 |
| BLA | Biologics License Application | Post-Phase 3 |
| sNDA | Supplemental NDA | Line extension |
| EUA | Emergency Use Authorization | Expedited |

### Regulatory Milestones

| Milestone | Significance |
|-----------|--------------|
| IND Clearance | Can begin human trials |
| Fast Track | Expedited review pathway |
| Breakthrough | Intensive FDA guidance |
| Priority Review | 6-month review |
| Standard Review | 10-12 month review |
| PDUFA Date | Decision deadline |
| Approval | Can commercialize |

## Portfolio Summary Analysis

### Pipeline Inventory

| Stage | Count | Key Programs |
|-------|-------|--------------|
| Approved | 2 | COVID vaccine, RSV |
| Phase 3 | 6 | CMV, Flu, Norovirus |
| Phase 2 | 8 | Oncology programs |
| Phase 1 | 10 | Early candidates |
| Preclinical | 15+ | Discovery programs |

### Portfolio Value Framework

```
Pipeline Valuation Approach:

Approved Products:
- Revenue projection × multiple

Phase 3 Candidates:
- Peak sales potential × probability (60%)

Phase 2 Candidates:
- Peak sales potential × probability (30%)

Phase 1 Candidates:
- Option value × probability (15%)

Total Pipeline Value: Sum of risk-adjusted values
```

## Catalyst Calendar

### Building a Catalyst Tracker

| Catalyst | Product | Timeline | Impact |
|----------|---------|----------|--------|
| Phase 3 Data | CMV Vaccine | 2025 | High |
| FDA Decision | Product X | Q2 2025 | Very High |
| Phase 2 Interim | Oncology | Q3 2025 | Medium |
| IND Filing | New Program | Q4 2025 | Low |

### Catalyst Risk Assessment

| Factor | Lower Risk | Higher Risk |
|--------|------------|-------------|
| Phase | Later stage | Earlier stage |
| Endpoint | Objective | Subjective |
| Trial Size | Large | Small |
| Prior Data | Positive | Mixed |
| Competition | Limited | Crowded |

## Sector-Specific Considerations

### Biotech/Pharma

| Focus Area | Key Metrics |
|------------|-------------|
| Clinical Data | Efficacy, safety |
| Regulatory Path | FDA interactions |
| Commercial | Market size, pricing |
| Manufacturing | Capacity, supply |

### Technology

| Focus Area | Key Metrics |
|------------|-------------|
| Product Launches | Timing, features |
| Beta Programs | User feedback |
| GA Release | Availability |
| Feature Roadmap | Future capabilities |

### Consumer Products

| Focus Area | Key Metrics |
|------------|-------------|
| New SKUs | Product variants |
| Distribution | Retail expansion |
| Marketing | Launch support |
| Consumer Testing | Reception data |

## Use Cases

1. **Pipeline Valuation**: Assess portfolio value
2. **Catalyst Trading**: Track binary events
3. **Competitive Analysis**: Compare pipelines
4. **R&D Assessment**: Evaluate innovation
5. **Investment Thesis**: Validate growth drivers
6. **Risk Analysis**: Identify pipeline gaps

## Combining with Other Skills

| Skill | Combined Analysis |
|-------|-------------------|
| earnings-capital-allocation | R&D investment vs. pipeline |
| sec-10k-analysis | Full pipeline disclosure |
| earnings-competitive-review | Pipeline vs. competitors |
| analyst-estimates | Pipeline in consensus |
| stock-price-change | Catalyst impact on price |

## Analysis Tips

1. **Track Timelines**: Note when data is expected

2. **Compare to Prior Quarters**: What advanced or slipped?

3. **Assess Probability**: Apply success rates by stage

4. **Watch for Delays**: Slipping timelines signal issues

5. **Competitor Context**: How does pipeline compare?

6. **Commercial Potential**: Estimate peak sales for key assets

## Interpreting Results

See [references/interpreting-results.md](references/interpreting-results.md) for detailed guidance on analyzing product pipeline updates.

© OctagonAI · MIT · OctagonAI/skills

Similar skills

All skills for Finance and business →

From the same set67

The whole set →
sec-business-desc-analysis sec-business-desc-analysis — a skill for Claude Code, Codex, Cursor, GitHub Copilot, and Gemini CLI that pulls business descriptions and competitive landscape data from SEC filings via Octagon MCP. CX Codex +1 266installs balance-sheet-growth balance-sheet-growth fetches year-over-year changes for major balance-sheet lines. Use it to examine liquidity, leverage, assets, equity, cash, and inventories. CX Codex +1 266installs stock-price-change Fetches stock price changes across ten periods — from one day to ten years. Builds a picture of momentum and trends on all horizons. CX Codex +1 266installs company-market-cap company-market-cap fetches the market capitalization of one publicly traded company through Octagon MCP. Use it to check company size or put a valuation in context. CX Codex +1 266installs historical-financial-ratings historical-financial-ratings fetches historical ratings and core financial metric grades for public tickers via Octagon MCP. CX Codex +1 265installs batch-market-cap batch-market-cap — a skill for Claude Code, Codex, Cursor, GitHub Copilot, and Gemini CLI that pulls market capitalization data for a list of tickers in one call via Octagon MCP. CX Codex +1 265installs stock-performance The stock-performance skill retrieves daily closing prices, trading volumes, and performance metrics via Octagon MCP. Analyze trends, compare stocks, or assess volatility. CX Codex +1 265installs earnings-capital-allocation The earnings-capital-allocation skill pulls capital plans, shareholder returns, M&A signals, and investment priorities from earnings call transcripts. CX Codex +1 264installs

Project sponsors

Companies that keep this analytics open